SCHEMBL3175443

SCHEMBL3175443

CCc1ncccc1CC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.59
CYP1A2 P05177 1/20 0.59
MAPT P10636 1/20 0.59
AKR1B1 P15121 1/20 0.46
CYP19A1 P11511 1/20 0.41
PTGS2 P35354 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PLA2G2A P14555 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
PDE4A P27815 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11273488 0.87 KDM4E (0.56) KDM4ECYP1A2MAPTAKR1B1CYP19A1
SCHEMBL11147053 0.87 KDM4E (0.65) KDM4ECYP1A2MAPTAKR1B1NAPRT
SCHEMBL28542523 0.84 KDM4E (0.41) KDM4ECYP1A2MAPTTDP1PDE4A
SCHEMBL18481212 0.83 MAPT (0.42) KDM4ECYP1A2MAPTKMT2ATDP1
SCHEMBL242311 0.82 GABRA1 (0.41) KDM4ECYP1A2MAPTPDE4A
Ammonia Solution, Strong SCHEMBL25385979 0.81 GABRA1 (0.39) KDM4ECYP1A2MAPTPDE4A
SCHEMBL5786722 0.81 GABRA1 (0.39) KDM4ECYP1A2MAPTPDE4A
SCHEMBL11248912 0.79 TDP1 (0.50) KDM4ECYP1A2MAPTAKR1B1CYP19A1
Hydrochloric Acid SCHEMBL28665184 0.79 GABRA1 (0.38) KDM4ECYP1A2MAPTPDE4A
Hydrochloric Acid SCHEMBL28880679 0.78 KDM4E (0.54) KDM4ECYP1A2MAPTAKR1B1NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630742-B2 Polishing composition using polishing particles containing basic substance and having high water affinity NISSAN CHEMICAL CORPORATION (JP) 2026-05-19 US disclosed
US-20220228031-A1 POLISHING COMPOSITION USING POLISHING PARTICLES CONTAINING BASIC SUBSTANCE AND HAVING HIGH WATER AFFINITY NISSAN CHEMICAL CORPORATION (JP) 2022-07-21 US disclosed
CN-110720030-A Temperature evaluation system and article management system using the same 株式会社日立制作所 2020-01-21 CN disclosed
US-9085572-B2 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-07-21 US disclosed
US-20120322772-A1 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-20 US disclosed
US-8252817-B2 Dipyridyl-dihydropyrazolones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-28 US disclosed
US-7816360-B2 Microsomal triglyceride transfer protein (MTP) inhibitors, used for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and non-insulin dependent diabetes JANSSEN PHARMACEUTICA NV (BE) 2010-10-19 US disclosed
US-20100219397-A1 TRANSITION METAL COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2010-09-02 US disclosed
US-20100035906-A1 Dipyridyl-dihydropyrazolones and their use BAYER HEALTHCARE AG (DE) 2010-02-11 US disclosed
US-20100004263-A1 MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES MEERPOEL LIEVEN 2010-01-07 US disclosed
CN-1192015-C Cell adhesion inhibitors BIOGEN INC (US) 2005-03-09 CN disclosed
US-6855715-B1 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-02-15 US disclosed
US-20050032790-A1 For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines LIEBESCHUETZ JOHN WALTER (GB) 2005-02-10 US disclosed
EP-1192135-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2002-04-03 EP disclosed
EP-1192132-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2002-04-03 EP disclosed
WO-2000076970-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
WO-2000076971-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
CN-1177343-A Cell adhesion inhibitors BIOGEN INC (US) 1998-03-25 CN disclosed
EP-0060144-A2 Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-09-15 EP disclosed
US-4336253-A Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100219397-A1 TRANSITION METAL COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME EPCAM, OR10J3, MYH9 KDM4E 1485/4885CYP1A2 3427/4885MAPT 162/4885
US-20050032790-A1 For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines SERPINB1, SERPINE1, SERPINH1 KDM4E 712/4885CYP1A2 728/4885MAPT 4609/4885
US-20120322772-A1 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES PPIP5K2, THPO, DPYD KDM4E 1847/4885CYP1A2 2614/4885MAPT 4811/4885
US-12630742-B2 Polishing composition using polishing particles containing basic substance and having high water affinity POLR1A, PRMT1, SRRM2 KDM4E 3297/4885CYP1A2 4248/4885MAPT 3328/4885
US-20100035906-A1 Dipyridyl-dihydropyrazolones and their use DPP7, DPP4, QDPR KDM4E 1823/4885CYP1A2 2583/4885MAPT 4676/4885
US-20100004263-A1 MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES PNLIP, LPL, APOB KDM4E 2768/4885CYP1A2 1911/4885MAPT 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.